AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
Open original sourceLoading market dashboard
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
Open original source